Violet Guhanshan or abandon Nanyue pharmaceutical great good matchmaking Hansen

"Hansen and the ancient Han stock price rise recently, because of the purple-violet ancient Han share company Nanyue Pharmaceutical, there have been many wonderful stories."　　"December 4, Hunan Capital market people to reporters. In late September to the end of November, Hunan two listed pharmaceutical companies in the Han-sen Pharmaceutical (002412).　　SZ) and Violet Guhanshan (000590.SZ) soared up to 35% and 95% respectively, to win the Shanghai index and the medical index. Behind the madness, two companies have been 挟裹 into Hunan's only blood products enterprises-Nanyue Pharmaceutical Co., Ltd. (hereinafter referred to as Nanyue pharmaceutical) of the stock disputes: Violet Guhanshan due to good performance and involved in the "direct" business, the road to profitability is becoming wider, intends to give up the Nanyue pharmaceutical equity　　And with the power of the listing of the Sen Pharmaceutical and its major shareholder Hainan Hansen Investment Co., Ltd. (hereinafter called Hanson Investment), by virtue of the strength of the capital coveted Nanyue pharmaceutical, to mediate Nanyue pharmaceutical equity dispute.　　Insiders say Nanyue, a large shareholder of the company, the controlling shareholder of the Gottia, Shenzhen Great Investment Group Co., Ltd. (hereinafter referred to as), in Guhanshan with the violet light on Nanyue pharmaceutical control negotiations deadlocked, borrow Li Hanson Investment Chairman Liu Linghan Mediate equity disputes, and possibly by Hanson Investment Nanyue Pharmaceutical, intervention in the biopharmaceutical field. "Violet Guhanshan's direct marketing prospects and its legitimacy is still doubtful, and Nanyue Pharmaceutical can spend the investment of Hansen also depends on the game results."　　"The research director of CITIC Investment Hunan headquarters, Dr. Liu Yahui."　　Purple ancient Han "salted fish" since August 2000 purple Light group into the Guhanshan after eight years, the performance of listed companies have been wandering. "Traditional Chinese medicine products are single, Western medicine is still inferior." "Days congenial analysis report that, purple-violet ancient Han income of more than 60% and more than 80% of the gross profit from proprietary Chinese medicine, and almost all of the Chinese medicine revenue from Guhanshan Health essence."　　Product single and main sales market holed up in Hunan, coupled with the loss of diversification of the company, many factors seriously affect performance growth.　　2009, purple Ancient Han management Big "exchange", including chairman, president, including many senior executives, the new management team took office, the major shareholder of Tsinghua Violet Group of listed companies to strengthen the control, the company's performance began to gradually improve. According to the results, Purple light Guhanshan 2009 to increase the proportion of assets impairment from 50% to 100%, so that the company 2010 years to reduce the amount of losses, the company's performance began to turn good.　　In spite of the company's huge loss of 88.17 million yuan in 2009, but 2010 years ago three quarters, the purple and ancient Chinese to achieve revenue 214 million yuan, net profit of 25 million yuan, year-on-year increase of 13.47% and 655.66% respectively. Sales of traditional products increased, violet Guhanshan also involved in the "direct" field.　　Reporter learned that the current purple violet ancient Han has no direct sales license, but the company and the natural person Chen Lipo Joint venture set up the Violet Guhanshan Technology Development Co., Ltd. (hereinafter called Violet Technology), is a large number of direct sales business in Hunan. December 2, Changsha Chiaki High-tech Park Violet Technology Office, a Liu surnamed staff told reporters that the company is purpleLight Guhanshan subsidiary, the implementation of the "upgrade direct, compatible with the traditional" model, as long as the payment of 10,000 yuan enrollment fee can be 20,000 yuan of ancient Chinese products (including health products, water purifier, etc.), but also to introduce other people to join. Although Violet Guhanshan denied participation in direct marketing, said "Violet technology and we have nothing to do with", but the reporter looked at business information and the annual report of the purple-violet ancient Han Dynasty, purple-violet technology was established in February 2006 by the Purple Guhanshan and Chen Lipo, and by the Violet Guhanshan 2006 fourth session of the Board of Directors　　Violet Science and technology has been established in the purple Ancient Han Hengyang in the factory Courtyard office, until September 2009 to move to Changsha office. Perhaps the market believes that the prospect of direct marketing is good, plus the purple ancient Han if the transfer of Nanyue pharmaceutical 36% stake, will increase investment income of tens of millions of yuan.　　Multiple positive stimulation, violet Guhanshan has been riding the momentum. Business performance to good, so deep Nanyue pharmaceutical stock dispute mire of Violet Guhanshan finally have "hero broken wrist" courage.　　The reporter learned that guhanshan and violet light on the latter exit Nanyue pharmaceutical negotiations has come to an end, and will introduce Hansen investment, through a stake in the king of biological indirect Nanyue pharmaceutical.　　Nanyue Pharmaceutical Chess gradually Ming Nanyue Pharmaceutical is one of the few blood products company, in 1999 after conversion, in 2000, became the Violet Ancient Man company. As a result of Nanyue pharmaceutical production of human blood albumin and immunoglobulin and other blood products sales price is high, the market prospects are broad, so many strategic investors in the eyes of the "sweet cakes."　　2005, the scene of biological as a strategic investor in Nanyue Pharmaceutical, accounted for 5%, Violet Ancient Han shareholding 95%.　　Since then, in the King of Biological chairman Mao JINWU and Violet Guhan President Liu Arrow Joint operation, through a series of equity resell, to December 2006, Nanyue the proportion of pharmaceutical shares changed to 60%, Violet Ancient Han 36%, King's biological general manager Zhang 4%. Nanyue's internal audit report shows that it has been profitable 2007 years later. According to the company's responsible person, Nanyue pharmaceutical under the 198 mu of land, plus the blood products license and drug approval (medicine number) and other intangible assets, the total assets of more than 300 million yuan, such as not to consider reasonable tax avoidance and amortization factors, Nanyue Pharmaceutical 2009 net profit of about 30 million yuan,　　2010 pre-tax profit is expected to reach 80 million-100 million yuan. Because of this, the 2009 Purple violet Ancient Chinese management, the new leadership to take back Nanyue pharmaceutical control.　　December 2009, received a report of the Hengyang Public Security Bureau in the name of alleged misappropriation of state assets, such as Mao Jinwu and Liu Arrow and other people in criminal detention. Prior to that, the king of Biological blood station assets and the Nanyue pharmaceutical has been stripped, so the pharmaceutical become the King of biological only the remaining quality assets.　　July 2006 and November 2009, great Jia through the increase in capital and equity assignee, the holding of Nanyue biological 95.45%, and then indirectly control the pharmaceutical industry. At the beginning of 2010, Gottia Mao Jinwu and Violet Guhanshan negotiations, but by Violet Guhanshan refused. People familiar with the matter saidAfter the deadlock, Gottia found Hanson Investment Chairman Liu Linghan for good offices, Liu Linghan in Hunan political and business relations widely, after Mao Jinwu release custody, tripartite negotiations restart, Violet Guhanshan also willing to quit Nanyue pharmaceutical of the price to pay the issue renegotiation. At the same time, he introduced Hanson Investment as a strategic investor to invest in the scene of life, the two sides will each investment 30 million yuan in the generation of the King of biological repayment of the 60 million yuan debt owed to the bank, and then through the creditor's rights, the joint control of the scene of life.　　As for the only remaining major asset of Nanyue Pharmaceuticals, the two sides will follow up with two sets of options: either by packaging it with a good holding subsidiary, Jiangxi Boya Biopharmaceutical Co., or by Hansen's investment. "In the aftermath of the 2008-year product deaths in Jiangxi province, there may be obstacles to listing in the short term, and Hansen's compensation for the bio-debt will not be the same, so it is more likely that Hansen can invest in the purchase."　　Liu Yahui bluntly.　　Hanson Investment Capital Impulse Hanson Investment Holdings of the Han-sen pharmaceutical, the main products for four grinding soup, such as oral liquid, the company landed on May 25, 2010 SSE SME Board, issued 19 million shares, raise capital of 648 million yuan to oral liquid and capsule production line technical renovation project. Hansen has seen rapid growth in its performance since the listing of the country's basic medicines and government subsidies. 2010.5 Annual report shows that the company's revenue of 151 million yuan to achieve net profit of 32.4927 million yuan, the year-on-year increase of 21.92% and 49.87% respectively.　　Among them, the list of national essential drugs, such as shrink-spring capsules, such as solid reagents income growth fastest, an increase of 83.34%. "Han Sen pharmaceutical industry in line with high gross profit margin, low debt and other typical characteristics."　　"Xiang Wealth securities researcher Ye Shi analysis, Hanson 2009 gross profit margin as high as 76.2%, and the ratio of assets and liabilities only 27.38%, with the company's success ipo,2010 three quarters of the company's assets and liabilities to 5.36%," this data will be reduced in the future. The very low rate of asset-liability Henkel Pharmaceuticals has a lot of cash.　　The company originally proposed to raise capital 155 million yuan, but due to the final issue of 55 times times earnings, the company raised a total of 648 million yuan, super raise 493 million yuan, over the proportion of up to 318%.　　The huge cash in hand Hansen's investment intention to acquire the King's biology and indirect holding Nanyue pharmaceutical, while the latter blood products asset quality, after the acquisition does not rule out will be injected into the listed companies, which also makes Hanson pharmaceutical Market imagine a broader space. The reporter learned from insider, Hanson Investment in addition to the king of the living creature, but also participate in the Han pharmaceutical upstream enterprise Chu-day technology.　　Chu-day science and technology was founded in 2000, is the domestic bio-pharmaceutical packaging machinery leading enterprises, its production of oral liquid bottle-washing and baking-sealing linkage line, is Hansen Pharmaceutical packaging equipment major drugs.　　Public reports show that Hansen Pharmaceutical 2009 newly launched three oral liquid production line equipment selection, high order in the CHU days of technology production of oral liquid bottle washing baking and sealing linkage line. "Hansen canThe stake in Chu-day technology, and Liu Linghan in Hunan political and business relations are not unrelated.　　"Hunan pharmaceutical industry personage said, Chu Tian technology has been listed in Hunan Province IPO key cultivation Enterprise list," So far no one venture investment can buy a stake. Perhaps by the acquisition of Nanyue Pharmaceutical, high distribution and other expected impact, September 21 to November 25, Hansen's pharmaceutical shares rose nearly 35%, leading the same period index and the growth of the medical indicators.